clonidine has been researched along with Vasospasm, Intracranial in 3 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Vasospasm, Intracranial: Constriction of arteries in the SKULL due to sudden, sharp, and often persistent smooth muscle contraction in blood vessels. Intracranial vasospasm results in reduced vessel lumen caliber, restricted blood flow to the brain, and BRAIN ISCHEMIA that may lead to hypoxic-ischemic brain injury (HYPOXIA-ISCHEMIA, BRAIN).
| Excerpt | Relevance | Reference |
|---|---|---|
| " The first group was used as control group (Control) (n = 20), in the second group subarachnoid hemorrhage was performed (SAH) (n = 20), in the third group Tizanidine was administered in addition to SAH (SAH + Tizanidine administration) (n = 20)." | 3.70 | The effect of tizanidine on chronic vasospasm in rats. ( Berkman, MK; Berkman, MZ; Erbengi, T; Iplikçioğlu, AC; San, T; Sav, A, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Treggiari, MM | 1 |
| Romand, JA | 1 |
| Martin, JB | 1 |
| Reverdin, A | 1 |
| Rüfenacht, DA | 1 |
| de Tribolet, N | 1 |
| Bunc, G | 1 |
| Kovacic, S | 1 |
| Strnad, S | 1 |
| Berkman, MZ | 1 |
| Iplikçioğlu, AC | 1 |
| Berkman, MK | 1 |
| Erbengi, T | 1 |
| San, T | 1 |
| Sav, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cervical Sympathetic Block to Increase Cerebral Blood Flow in Patients With Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage[NCT05230134] | 10 participants (Anticipated) | Interventional | 2023-07-27 | Enrolling by invitation | |||
| Stellate Ganglion Block for the Treatment of COVID-19-Induced Olfactory Dysfunction: A Prospective Pilot Study[NCT05445921] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2022-09-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Participants will be asked to complete the ODOR, which is a patient-reported outcome measure assessing physical problems, functional limitations, and emotional consequences of olfactory dysfunction.~The ODOR has a minimum score of 0 and a maximum score of 112 with higher scores indicating a greater degree of impairment and limitation. The minimal clinically important difference is a change of 15 points." (NCT05445921)
Timeframe: baseline, 5-10 days post SGB #1, and 1 month
| Intervention | score on a scale (Median) | ||
|---|---|---|---|
| ODOR at Baseline | ODOR at 1 Week | ODOR at 1 Month | |
| Stellate Ganglion Block | 62 | 57 | 50.5 |
"Participants will complete the 40-item scratch and sniff UPSIT and mean change will be assessed.~The UPSIT has a minimum score of 0 and maximum score of 40 with lower scores indicating a greater degree of impairment. An UPSIT score of >33 for men and >34 for women is considered normosmic, and the minimal clinically important difference is a change of 4 points." (NCT05445921)
Timeframe: baseline, 5-10 days, and 1 month
| Intervention | units on a scale (Median) | ||
|---|---|---|---|
| UPSIT at Baseline | UPSIT at 1 Week | UPSIT at 1 Month | |
| Stellate Ganglion Block | 16.5 | 21 | 22.5 |
Participants will be asked about their change in olfactory dysfunction on a 7-point Likert scale from much better to much worse. (NCT05445921)
Timeframe: 5-10 days post SGB #1 and 1 month
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGI-I for Smell Loss at 1 Week71922197 | CGI-I for Smell Loss at 1 Month71922197 | CGI-I for Smell Distortion at 1 Week71922197 | CGI-I for Smell Distortion at 1 Month71922197 | CGI-I for Taste Loss at 1 Week71922197 | CGI-I for Taste Loss at 1 Month71922197 | CGI-I for Taste Distortion at 1 Week71922197 | CGI-I for Taste Distortion at 1 Month71922197 | |||||||||||||||||||||||||
| About the Same | Slightly Better | Much Better | Moderately Better | |||||||||||||||||||||||||||||
| Stellate Ganglion Block | 8 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 10 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 9 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 11 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 6 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 1 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 15 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 4 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 0 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 14 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 3 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 2 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 13 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 12 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 5 | |||||||||||||||||||||||||||||||
Participants will be asked about the severity of their olfactory dysfunction (and gustatory dysfunction) on a 5-point Likert scale from no smell loss to severe smell loss. (NCT05445921)
Timeframe: baseline, 5-10 days, and 1 month
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGI-S for Smell Loss at Baseline71922197 | CGI-S for Smell Loss at 1 Week71922197 | CGI-S for Smell Loss at 1 Month71922197 | CGI-S for Smell Distortion at Baseline71922197 | CGI-S for Smell Distortion at 1 Week71922197 | CGI-S for Smell Distortion at 1 Month71922197 | CGI-S for Taste Loss at Baseline71922197 | CGI-S for Taste Loss at 1 Week71922197 | CGI-S for Taste Loss at 1 Month71922197 | CGI-S for Taste Distortion at Baseline71922197 | CGI-S for Taste Distortion at 1 Week71922197 | CGI-S for Taste Distortion at 1 Month71922197 | |||||||||||||||||||||||||||||||||||||||||||||||||
| No Problem | Very Mild Problem | Mild Problem | Moderate Problem | Severe Problem | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 trial available for clonidine and Vasospasm, Intracranial
| Article | Year |
|---|---|
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
2 other studies available for clonidine and Vasospasm, Intracranial
| Article | Year |
|---|---|
Attenuation of cerebral vasospasm in rabbits using clonidine hydrochloride, a central adrenergic agonist.
Topics: Adrenergic alpha-Agonists; Animals; Clonidine; Dopamine beta-Hydroxylase; Rabbits; Vasospasm, Intrac | 2003 |
The effect of tizanidine on chronic vasospasm in rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Chronic Disease; Clonidine; Disease Models, Animal; F | 2000 |